Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04338061

Recruitment Status : Terminated (Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide in both studies.)

First Posted : April 8, 2020

Last Update Posted : April 29, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

EMD Serono Research & Development Institute, Inc.

Information provided by (Responsible Party):

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	October 2, 2023
Actual Study Completion Date :	March 19, 2024

To Top